Event Date/Time: Jul 12, 2007 End Date/Time: Jul 13, 2007
Registration Date: Jun 15, 2007
Early Registration Date: May 18, 2007
Report as Spam


The amorphous state is becoming increasingly important in industrial drug development as companies are now turning more often to this form to improve the bioavailability and efficacy of their drug products. In this interactive meeting, the challenges and opportunities that are involved in developing amorphous products will be discussed in detail with industrial and academic perspectives.

Join Amorphous Pharmaceutical Materials in Amsterdam this summer to find out how to:

Understand the behaviour of amorphous and disordered materials to improve your drug development processes
Effectively characterise the amorphous form using traditional and novel techniques
Assess the stability of amorphous systems and the resulting implications in product development
Consider and control both chemical and physical stability of amorphous pharmaceuticals
Improve your approaches to formulation and physical characterisation of solid dispersions
Explore the patentability of amorphous materials to maximise the protection of your intellectual property


Planeetbaan 2

Additional Information

Narayan Variankaval, Research Fellow, Merck Research Laboratories Anne Kavanagh, Crystallisation Scientist, AstraZeneca Guy Van den Mooter, Professor, Pharmacotechnology and Biopharmacy, University of Leuven Bill Jones, Pfizer Institute for Pharmaceutical Materials, University of Cambridge Bertrand Gellie, Director of Organic Chemistry, European Patent Office Rolf Hilfiker, Head of Department, Solid–State Development, Solvias AG Marco Geppi, Deparment of Chemistry and Industrial Chemistry, University of Pisa Rahul Surana, Group Leader, Preformulation, Forest Laboratories Paul Royall, Lecturer in Pharmaceutics, University of East Anglia